NCT06999057 Quadriceps Motor Unit Adaptation to Simulated Knee Injury
| NCT ID | NCT06999057 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Central Florida |
| Condition | Muscle Inhibition |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 45 participants in total. It began in 2026-08-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates how simulated knee injury-via artificial joint effusion or deafferentation-affects quadriceps motor unit behavior in healthy young adults. Participants will complete neuromuscular testing during a single 2-hour lab session. This research seeks to improve understanding of muscle inhibition and inform interventions after real-world knee trauma.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-30 years 2. Physically active (Tegner ≥ 5) 3. No prior lower-limb surgery or major injury Exclusion Criteria: 1. Lower limb surgery or significant injury in past 2 years 2. Cardiopulmonary, neurological, or psychiatric disorders 3. Needle/electrical stimulation anxiety 4. Medications affecting neuromuscular or psychological function 5. Pregnancy 6. Allergic to lidocaine 7. Inability to elicit Hoffmann reflex
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06999057 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Muscle Inhibition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06999057 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06999057 currently recruiting?
Yes, NCT06999057 is actively recruiting participants. Contact the research team at Grant.Norte@ucf.edu for enrollment information.
Where is the NCT06999057 trial being conducted?
This trial is being conducted at Orlando, United States.
Who is sponsoring the NCT06999057 clinical trial?
NCT06999057 is sponsored by University of Central Florida. The trial plans to enroll 45 participants.